Search Images Maps Play YouTube News Gmail Drive More »
Advanced Patent Search | Web History | Sign in

Patents

Embodiments of the invention provide processes for the selection of HIV-1 subtype (clade) C isolates, selected HIV-1 subtype C isolates, their genes and modifications and derivatives thereof for use in prophylactic and therapeutic vaccines to produce proteins and polypeptides for the purpose of eliciting protection against HIV infection or disease. A process for the selection of HIV subtype isolates comprises the steps of isolating viruses from recently infected subjects; generating a consensus sequence for at least part of at least one HIV gene by identifying the most common codon or amino acid among the isolated viruses; and selecting the isolated virus or viruses with a high sequence identity to the consensus sequence. HIV-1 subtype C isolates, designated Du422, Du 151 and Du 179 (assigned Accession Numbers 01032114, 00072724 and 00072725, respectively, by the European Collection of Cell Cultures) are also provided.

Inventors: Robert Edward Johnston, Salim Abdol Karim, Lynn Morris, Ronald Swanstrom, Carolyn Williamson
Original Assignees: Medical Research Council, University of Cape Town Observatory, University of North Carolina at Chapel Hill, Alphavax, Incorporated
Primary Examiner: Jeffrey S. Parkin
Attorney: Kilpatrick Townsend & Stockton LLP
Current U.S. Classification: 536/23.72; 424/188.1

View patent at USPTO
Search USPTO Assignment Database

Citations

Cited PatentFiling dateIssue dateOriginal AssigneeTitle
US5817637Jan 13, 1997Oct 6, 1998The Trustees of the University of Pennsylvania
The Wistar Institute		Genetic immunization
US20050137387Feb 17, 2004University of Washington Office of Technology LicensingAncestral and COT viral sequences, proteins and immunogenic compositions

Claims

1. An isolated nucleic acid molecule comprising a sequence that encodes an HIV Gag polypeptide as set forth in SEQ ID NO: 8, or a sequence at least 98% genetically related to the full-length sequence of SEQ ID NO: 8.

2. The isolated nucleic acid molecule of claim 1 wherein the HIV gag polypeptide is as set forth in SEQ ID NO: 2.

3. The isolated nucleic acid molecule of claim 1 comprising:

(i) the sequence as set forth in SEQ ID NO: 1 or a sequence at least 98% genetically related to the full-length sequence of SEQ ID NO:1;

(ii) the sequence as set forth in SEQ ID NO: 1 modified to remove a myristylation site and to reflect human codon usage;

(iii) the sequence as set forth in SEQ ID NO: 7 or a sequence at least 98% genetically related to the full-length sequence of SEQ ID NO: 7;

(iv) a sequence which is complementary to (i)-(iii); or (v) an RNA sequence encoded by (i)-(iv).

4. An isolated polypeptide comprising the Gag sequence as set forth in SEQ ID NO: 2 or as set forth in SEQ ID NO: 8, or a sequence at least 98% genetically related to the full-length sequence of SEQ ID NO: 2 or at least 98% genetically related to the full-length sequence of SEQ ID NO: 8.

5. A composition comprising a nucleic acid molecule comprising a sequence that encodes an HIV Gag polypeptide as set forth in SEQ ID NO: 2 or as set forth in SEQ ID NO: 8, or a sequence at least 98% genetically related to the full-length sequence of SEQ ID NO: 2 or at least 98% genetically related to the full-length sequence of SEQ ID NO: 8, in a pharmaceutical carrier.

6. The composition of claim 5, wherein the nucleic acid molecule comprises:

the sequence as set forth in SEQ ID NO: 1 or a sequence at least 98% genetically related to the full-length sequence of SEQ ID NO: 1;

(ii) the sequence as set forth in SEQ ID NO: 1 modified to remove a myristylation site and to reflect human codon usage;

(iii) the sequence as set forth in SEQ ID NO: 7 or a sequence at least 98% genetically related to the full-length sequence of SEQ ID NO: 7;

(iv) a sequence which is complementary to (i)-(iii); or
(v) an RNA sequence encoded by (i)-(iv).

Drawings